The LDBC Graphalytics Benchmark

In this document, we describe LDBC Graphalytics, an industrial-grade benchmark for graph analysis platforms. The main goal of Graphalytics is to enable the fair and objective comparison of graph analysis platforms. Due to the diversity of bottlenecks and performance issues such platforms need to address, Graphalytics consists of a set of selected deterministic algorithms for full-graph analysis, standard graph datasets, synthetic dataset generators, and reference output for validation purposes. Its test harness produces deep metrics that quantify multiple kinds of systems scalability, weak and strong, and robustness, such as failures and performance variability. The benchmark also balances comprehensiveness with runtime necessary to obtain the deep metrics. The benchmark comes with open-source software for generating performance data, for validating algorithm results, for monitoring and sharing performance data, and for obtaining the final benchmark result as a standard performance report

Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic

Evidence on the effectiveness of COVID-19 vaccines among people who recovered from a previous SARS-CoV-2 infection is warranted to inform vaccination recommendations. Using the territory-wide public healthcare and vaccination records of over 2.5 million individuals in Hong Kong, we examined the potentially differential risk of SARS-CoV-2 infection, hospitalization, and mortality between those receiving two homologous doses of BNT162b2 or CoronaVac versus those with a previous infection receiving only one dose amid the Omicron epidemic. Results show a single dose after a SARS-CoV-2 infection is associated with a lower risk of infection (BNT162b2: adjusted incidence rate ratio [IRR] = 0.475, 95% CI: 0.410–0.550; CoronaVac: adjusted IRR = 0.397, 95% CI: 0.309–0.511) and no significant difference was detected in the risk of COVID-19-related hospitalization or mortality compared with a two-dose vaccination regimen. Findings support clinical recommendations that those with a previous infection could receive a single dose to gain at least similar protection as those who received two doses without a previous infection

LDBC Graphalytics: A Benchmark for Large-Scale Graph Analysis on Parallel and Distributed Platforms

ABSTRACT In this paper we introduce LDBC Graphalytics, a new industrial-grade benchmark for graph analysis platforms. It consists of six deterministic algorithms, standard datasets, synthetic dataset generators, and reference output, that enable the objective comparison of graph analysis platforms. Its test harness produces deep metrics that quantify multiple kinds of system scalability, such as horizontal/vertical and weak/strong, and of robustness, such as failures and performance variability. The benchmark comes with open-source software for generating data and monitoring performance. We describe and analyze six implementations of the benchmark (three from the community, three from the industry), providing insights into the strengths and weaknesses of the platforms. Key to our contribution, vendors perform the tuning and benchmarking of their platforms

Use of Miniplates and Local Bone Grafts to Prevent Spring Back in Laminoplasty for Cervical Spondylotic Myelopathy

Background/Purpose: Cervical spondylotic myelopathy/ossification of posterior longitudinal ligament can be treated by anterior or posterior decompression. For multiple levels, it is common to perform posterior decompression by laminoplasty. Hirabayashi described his open-door expansive laminoplasty in 1977, which soon became popular. Spring back of the lamina has always been a problem. Many methods including suturing to soft tissue, suture anchors, bone grafts, hydroxyapatite blocks, and ceramic spacers were used to prevent this problem, but with considerable failure. Recently, miniplates were used to prevent spring back. Methods: Twenty-nine consecutive patients who had underwent Hirabayashi open-door expansive laminoplasty in a single centre were recruited in this retrospective study. Miniplates were used to keep the laminae open. In addition, the spinous processes of lower cervical vertebrae were excised and used as local bone grafts to fill the gap between the cut laminae. Computerized tomography scans were performed postoperatively for all patients to assess bone union and spring back. Results: A total of 126 levels of laminoplasty and 51 local bone grafts were studied. The minimal follow-up period was 12 months. Signs of bone union were demonstrated in 123 hinges (97.6%) and 51 bone grafts (100%). No spring back was detected. The clinical outcome in terms of Hirabayashi recovery rate was 47.2%. Conclusion: Miniplates and local bone grafts are promising and effective tools for preventing spring back in cervical laminoplasty

LDBC Graphalytics: A Benchmark for Large-Scale Graph Analysis on Parallel and Distributed Platforms

In this paper we introduce LDBC Graphalytics, a new industrial-grade benchmark for graph analysis platforms. It consists of six deterministic algorithms, standard datasets, synthetic dataset generators, and reference output, that enable the objective comparison of graph analysis platforms. Its test harness produces deep metrics that quantify multiple kinds of system scalability, such as horizontal/vertical and weak/strong, and of robustness, such as failures and performance variability. The benchmark comes with open-source software for generating data and monitoring performance. We describe and analyze six implementations of the benchmark (three from the community, three from the industry), providing insights into the strengths and weaknesses of the platforms. Key to our contribution, vendors perform the tuning and benchmarking of their platforms

COVID-19 vaccines and risks of hematological abnormalities: nested case-control and self-controlled case series study

BACKGROUND: Several studies reported hematological abnormalities after vaccination against the coronavirus disease 2019 (COVID-19). We evaluated the association between COVID-19 vaccines (CoronaVac and BNT162b2) and hematological abnormalities. METHODS: We conducted nested case-control and self-controlled case series (SCCS) analyses using the data from the Hong Kong Hospital Authority and the Department of Health, HKSAR. Outcomes of interest were thrombocytopenia, leukopenia, and neutropenia. Adjusted odds ratios (aORs), incidence rate ratios (IRRs), and 95% confidence intervals (CIs) were estimated using conditional logistic regression. RESULTS: In total, 1,643,419 people received COVID-19 vaccination (738,609 CoronaVac; 904,810 BNT162b2). We identified 457 and 422 cases after CoronaVac and BNT162b2 vaccination, respectively. For CoronaVac, the incidence of thrombocytopenia, leukopenia, and neutropenia was 2.51, 1.08, 0.15 per 10,000 doses. For BNT162b2, the corresponding incidence were 1.39, 1.17, 0.26 per 10,000 doses. The incidence per 10,000 COVID-19 cases were 1,254, 2,341, and 884, respectively. We only observed an increased risk of leukopenia following the second dose of BNT162b2 (aOR 1.58, 95% CI 1.24 - 2.02; day0-14, IRR 2.21; 95% CI 1.59-3.08). There was no increased risk of any hematological abnormalities after CoronaVac vaccination. CONCLUSION: We observed an increased risk of leukopenia shortly after the second dose of BNT162b2. However, the incidence was much lower than the incidence following SARS-COV-2 infections. There was no association between CoronaVac and hematological abnormalities. The benefits of vaccination against COVID-19 still outweigh the risk of hematological abnormalities

Development and validation of risk prediction models for COVID-19 positivity in a hospital setting

ObjectivesTo develop: (1) two validated risk prediction models for coronavirus disease-2019 (COVID-19) positivity using readily available parameters in a general hospital setting; (2) nomograms and probabilities to allow clinical utilisation.MethodsPatients with and without COVID-19 were included from 4 Hong Kong hospitals. The database was randomly split into 2:1: for model development database (n = 895) and validation database (n = 435). Multivariable logistic regression was utilised for model creation and validated with the Hosmer-Lemeshow (H-L) test and calibration plot. Nomograms and probabilities set at 0.1, 0.2, 0.4 and 0.6 were calculated to determine sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).ResultsA total of 1330 patients (mean age 58.2 ± 24.5 years; 50.7% males; 296 COVID-19 positive) were recruited. The first prediction model developed had age, total white blood cell count, chest x-ray appearances and contact history as significant predictors (AUC = 0.911 [CI = 0.880-0.941]). The second model developed has the same variables except contact history (AUC = 0.880 [CI = 0.844-0.916]). Both were externally validated on the H-L test (p = 0.781 and 0.155, respectively) and calibration plot. Models were converted to nomograms. Lower probabilities give higher sensitivity and NPV; higher probabilities give higher specificity and PPV.ConclusionTwo simple-to-use validated nomograms were developed with excellent AUCs based on readily available parameters and can be considered for clinical utilisation

Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination : a self-controlled case series study

Background: This study aims to evaluate the association between thromboembolic events and hemorrhagic stroke following BNT162b2 and CoronaVac vaccination. Methods: Patients with incident thromboembolic events or hemorrhagic stroke within 28 days of covid-19 vaccination or SARS-CoV-2 positive test during 23 February to 30 September 2021 were included. The incidence per 100,000 covid-19 vaccine doses administered and SARS-CoV-2 test positive cases were estimated. A modified self-controlled case series (SCCS) analysis using the data from the Hong Kong territory-wide electronic health and vaccination records. Seasonal effect was adjusted by month. Findings: A total of 5,526,547 doses of BNT162b2 and 3,146,741 doses of CoronaVac were administered. A total of 334 and 402 thromboembolic events, and 57 and 49 hemorrhagic stroke cases occurred within 28 days after BNT162b2 and CoronaVac vaccination, respectively. The crude incidence of thromboembolic events and hemorrhagic stroke per 100,000 doses administered for both covid-19 vaccines were smaller than that per 100,000 SARS-CoV-2 test positive cases. The modified SCCS detected an increased risk of hemorrhagic stroke in BNT162b2 14-27 days after first dose with adjusted IRR of 2.53 (95% CI 1.48-4.34), and 0-13 days after second dose with adjusted IRR 2.69 (95% CI 1.54-4.69). No statistically significant risk was observed for thromboembolic events for both vaccines. Interpretation: We detected a possible safety signal for hemorrhagic stroke following BNT162b2 vaccination. The incidence of thromboembolic event or hemorrhagic stroke following vaccination is lower than that among SARS-CoV-2 test positive cases; therefore, vaccination against covid-19 remains an important public health intervention. Funding: This study was funded by a research grant from the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region (reference COVID19F01)